Investigating how inhibiting Pyk2 can affect bone mass
Uncovering the dual anabolic and anti-catabolic effects of Pyk2 inhibition on bone mass
['FUNDING_R01'] · INDIANA UNIVERSITY INDIANAPOLIS · NIH-10891456
This study is looking at how blocking a specific protein can help increase bone mass, especially for menopausal women and older adults, with the hope of finding new ways to treat osteoporosis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INDIANA UNIVERSITY INDIANAPOLIS (nih funded) |
| Locations | 1 site (INDIANAPOLIS, UNITED STATES) |
| Trial ID | NIH-10891456 on ClinicalTrials.gov |
What this research studies
This research explores the effects of inhibiting the Pyk2 tyrosine kinase on bone mass, particularly focusing on its dual role in bone formation and resorption. The study aims to understand how this inhibition can lead to increased bone mass, especially in menopausal women and aging individuals. By using animal models, researchers will assess the impact of Pyk2 inhibition on bone density and structure, potentially leading to new treatment options for osteoporosis. The approach includes examining the biological mechanisms involved and how they differ between sexes.
Who could benefit from this research
Good fit: Ideal candidates for this research are postmenopausal women and older adults experiencing bone loss.
Not a fit: Patients who are not experiencing bone loss or those with conditions unrelated to bone health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively increase bone mass and reduce the risk of fractures in at-risk populations.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for improving bone health, indicating potential for success in this approach.
Where this research is happening
INDIANAPOLIS, UNITED STATES
- INDIANA UNIVERSITY INDIANAPOLIS — INDIANAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRUZZANITI, ANGELA — INDIANA UNIVERSITY INDIANAPOLIS
- Study coordinator: BRUZZANITI, ANGELA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.